You are here: Industry Insights > Development

News List

3M Drug Delivery Systems Relocates UK R&D contractpharma
April 02, 2019
New R&D site covers more than 1,300 square meters of specifically-configured laboratory space for the development of inhalation therapies
Asymchem Completes HPAPI Facility Inspection contractpharma
March 28, 2019
Asymchem has announced that its Tianjin1 site, a dedicated High Potency Active Pharmaceutical Ingredients (HPAPI) development and manufacturing facility, successfully completed a U.S. Food and Drug Administration general GMP reinspection conducted between
Teva & Genedata Enter Biopharma Partnership contractpharma
March 27, 2019
Teva will use Genedata's workflow platform to streamline the identification, engineering, and characterization of novel biopharmaceuticals drugs.
WindMIL Therapeutics Announces Key Appointment contractpharma
March 27, 2019
WindMIL Therapeutics has announced the appointment of Sanjin Zvonić, PhD, as vice president of Process Science and Manufacturing.
VGXI Achieves Tech Transfer Milestones contractpharma
March 20, 2019
Relates to RNA manufacturing partnership with research inst. in Houston
Paratek Pharma Management Change contractpharma
March 19, 2019
Douglas Pagán resigns as CFO, Sarah Higgins to assume responsibilities on interim basis.
GTx and Oncternal Enter Merger pharmafocusasia
March 14, 2019
In addition, a ROR-1 targeted chimeric antigen receptor T-cell (CAdR-T) program is in preclinical development at UC San Diego for hematologic and solid tumors.
Envigo Launches PATHWAY contractpharma
March 13, 2019
Envigo has launched PATHWAY, an integrated solution designed to optimize non-clinical safety assessment programs to enable first-in-human clinical trials.
Uhlmann Appoints Regional Sales Manager contractpharma
March 12, 2019
Kevin Thompson has been named regional sales manager for the South-Central United States
Akili, Shionogi to develop digital therapeutics in key Asian markets biospectrumasia
March 11, 2019
Akili Interactive and Shionogi & Co. have announced that they have entered into a strategic partnership for the commercialization of Akili’s digital medicines, AKL-T01 and AKL-T02, in Japan and Taiwan, China region in China.

Previous page 1 2 3 4 5 6 Next page